De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic Polyangiitis
Vaccination against SARS-CoV-2 is the most important advance in the fight against the ongoing coronavirus pandemic. Recent case reports show that the SARS-CoV-2 vaccines can very rarely cause de novo or relapsing glomerular disease. Here, we report two female patients with microscopic polyangiitis,...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Case Reports in Nephrology |
| Online Access: | http://dx.doi.org/10.1155/2021/8400842 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832545940008861696 |
|---|---|
| author | Tamara Davidovic Judith Schimpf Hannelore Sprenger-Mähr Armin Abbassi-Nik Afschin Soleiman Emanuel Zitt Karl Lhotta |
| author_facet | Tamara Davidovic Judith Schimpf Hannelore Sprenger-Mähr Armin Abbassi-Nik Afschin Soleiman Emanuel Zitt Karl Lhotta |
| author_sort | Tamara Davidovic |
| collection | DOAJ |
| description | Vaccination against SARS-CoV-2 is the most important advance in the fight against the ongoing coronavirus pandemic. Recent case reports show that the SARS-CoV-2 vaccines can very rarely cause de novo or relapsing glomerular disease. Here, we report two female patients with microscopic polyangiitis, who developed severe glomerulonephritis after immunisation with the BNT162b2 mRNA vaccine. One patient with a possible ongoing but undiagnosed disease developed severe necrotising glomerulonephritis after the second vaccination. In the other patient with a long-lasting disease, rituximab maintenance therapy had been postponed because of the coronavirus pandemic. She noted macrohematuria immediately after the second vaccine dose and developed a severe renal relapse leading to end-stage kidney disease. We suggest that patients with ANCA-associated vasculitis be carefully monitored for disease activity immediately before and after receiving the SARS-CoV-2 vaccination, especially if maintenance therapy has been interrupted. Ultimately, mRNA vaccines should probably be avoided in these patients. |
| format | Article |
| id | doaj-art-a6ae0f07937947bfa89be190eea724de |
| institution | Kabale University |
| issn | 2090-6641 2090-665X |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Nephrology |
| spelling | doaj-art-a6ae0f07937947bfa89be190eea724de2025-02-03T07:24:22ZengWileyCase Reports in Nephrology2090-66412090-665X2021-01-01202110.1155/2021/84008428400842De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic PolyangiitisTamara Davidovic0Judith Schimpf1Hannelore Sprenger-Mähr2Armin Abbassi-Nik3Afschin Soleiman4Emanuel Zitt5Karl Lhotta6Department of Internal Medicine III (Nephrology and Dialysis), Feldkirch Academic Teaching Hospital, Feldkirch, AustriaDepartment of Internal Medicine III (Nephrology and Dialysis), Feldkirch Academic Teaching Hospital, Feldkirch, AustriaDepartment of Internal Medicine III (Nephrology and Dialysis), Feldkirch Academic Teaching Hospital, Feldkirch, AustriaDepartment of Internal Medicine III (Nephrology and Dialysis), Feldkirch Academic Teaching Hospital, Feldkirch, AustriaPathology, Cytodiagnostics and Molecular Pathology, Hall in Tirol, AustriaDepartment of Internal Medicine III (Nephrology and Dialysis), Feldkirch Academic Teaching Hospital, Feldkirch, AustriaDepartment of Internal Medicine III (Nephrology and Dialysis), Feldkirch Academic Teaching Hospital, Feldkirch, AustriaVaccination against SARS-CoV-2 is the most important advance in the fight against the ongoing coronavirus pandemic. Recent case reports show that the SARS-CoV-2 vaccines can very rarely cause de novo or relapsing glomerular disease. Here, we report two female patients with microscopic polyangiitis, who developed severe glomerulonephritis after immunisation with the BNT162b2 mRNA vaccine. One patient with a possible ongoing but undiagnosed disease developed severe necrotising glomerulonephritis after the second vaccination. In the other patient with a long-lasting disease, rituximab maintenance therapy had been postponed because of the coronavirus pandemic. She noted macrohematuria immediately after the second vaccine dose and developed a severe renal relapse leading to end-stage kidney disease. We suggest that patients with ANCA-associated vasculitis be carefully monitored for disease activity immediately before and after receiving the SARS-CoV-2 vaccination, especially if maintenance therapy has been interrupted. Ultimately, mRNA vaccines should probably be avoided in these patients.http://dx.doi.org/10.1155/2021/8400842 |
| spellingShingle | Tamara Davidovic Judith Schimpf Hannelore Sprenger-Mähr Armin Abbassi-Nik Afschin Soleiman Emanuel Zitt Karl Lhotta De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic Polyangiitis Case Reports in Nephrology |
| title | De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic Polyangiitis |
| title_full | De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic Polyangiitis |
| title_fullStr | De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic Polyangiitis |
| title_full_unstemmed | De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic Polyangiitis |
| title_short | De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic Polyangiitis |
| title_sort | de novo and relapsing glomerulonephritis following sars cov 2 mrna vaccination in microscopic polyangiitis |
| url | http://dx.doi.org/10.1155/2021/8400842 |
| work_keys_str_mv | AT tamaradavidovic denovoandrelapsingglomerulonephritisfollowingsarscov2mrnavaccinationinmicroscopicpolyangiitis AT judithschimpf denovoandrelapsingglomerulonephritisfollowingsarscov2mrnavaccinationinmicroscopicpolyangiitis AT hanneloresprengermahr denovoandrelapsingglomerulonephritisfollowingsarscov2mrnavaccinationinmicroscopicpolyangiitis AT arminabbassinik denovoandrelapsingglomerulonephritisfollowingsarscov2mrnavaccinationinmicroscopicpolyangiitis AT afschinsoleiman denovoandrelapsingglomerulonephritisfollowingsarscov2mrnavaccinationinmicroscopicpolyangiitis AT emanuelzitt denovoandrelapsingglomerulonephritisfollowingsarscov2mrnavaccinationinmicroscopicpolyangiitis AT karllhotta denovoandrelapsingglomerulonephritisfollowingsarscov2mrnavaccinationinmicroscopicpolyangiitis |